Cargando…

Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England

Background: Symptoms, severity, and acuteness of peripheral artery disease (PAD) are major determinants of severe limb symptoms, subsequent risk of cardiovascular events, and mortality. Lower-extremity revascularization (LER) is a key option to relieve symptoms and to prevent limb loss in symptomati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Portas, Laura, Bauersachs, Rupert, Bowrin, Kevin, Briere, Jean-Baptiste, Cohen, Alexander, Huelsebeck, Maria, Jones, Schuyler, Quint, Jennifer K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551319/ https://www.ncbi.nlm.nih.gov/pubmed/35670290 http://dx.doi.org/10.1177/1358863X221096704

Ejemplares similares

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
por: Bauersachs, Rupert, et al.
Publicado: (2019)

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis
por: Bauersachs, Rupert, et al.
Publicado: (2021)

Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization
por: Serra, Raffaele, et al.
Publicado: (2021)

Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
por: Kadoglou, Nikolaos P. E., et al.
Publicado: (2021)

Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
por: Hess, Connie N., et al.
Publicado: (2022)

Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease
por: Biswas, Minakshi P., et al.
Publicado: (2021)

Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study
por: Esposti, Luca D, et al.
Publicado: (2019)

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
por: Levy, Pierre, et al.
Publicado: (2019)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Is Paclitaxel Causing Mortality During Lower‐Extremity Revascularization?
por: Swaminathan, Rajesh V., et al.
Publicado: (2019)

Transpedal and Tibiopedal Retrograde Revascularization for Peripheral Vascular Disease
por: Ali, Nawaf M O S, et al.
Publicado: (2022)

Surgical infrainguinal revascularization for peripheral arterial disease: factors affecting patency rate
por: Jafarian, Ali, et al.
Publicado: (2015)

The Use of the Fasciocutaneous Flap Harvested From Revascularized Limbs With Peripheral Arterial Disease
por: Hwan Lee, Dong, et al.
Publicado: (2019)

Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review
por: Lavoie, Louis, et al.
Publicado: (2016)

Lower extremity amputation in peripheral artery disease: improving patient outcomes
por: Swaminathan, Aparna, et al.
Publicado: (2014)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Association of Ankle-Brachial Indices With Limb Revascularization or Amputation in Patients With Peripheral Artery Disease
por: Moussa Pacha, Homam, et al.
Publicado: (2018)

Endovascular Revascularization Improves the Central Hemodynamics and Augmentation Index in Patients with Peripheral Artery Disease
por: Watanabe, Ken, et al.
Publicado: (2019)

Evaluation of Hyperspectral Imaging for Follow-Up Assessment after Revascularization in Peripheral Artery Disease
por: Grambow, Eberhard, et al.
Publicado: (2022)

Effect of Revascularization on Intramuscular Vascular Endothelial Growth Factor Levels in Peripheral Arterial Disease
por: Schawe, Larissa, et al.
Publicado: (2022)

Distribution of Peripheral Arterial Disease in Patients Undergoing Endovascular Revascularization for Chronic Limb Threatening Ischaemia: Insights from the Vascular Quality Initiative in Singapore
por: Soon, Shereen X. Y., et al.
Publicado: (2021)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

The Importance of Patency in Patients with Critical Limb Ischemia Undergoing Endovascular Revascularization for Infrapopliteal Arterial Disease
por: Baumann, Frederic, et al.
Publicado: (2015)

Gender differences in quality of life in coronary artery disease patients with comorbidities undergoing coronary revascularization
por: Oreel, Tom H., et al.
Publicado: (2020)

Burden and treatment of chronic obstructive pulmonary disease among people using illicit opioids: matched cohort study in England
por: Lewer, Dan, et al.
Publicado: (2022)

Prevalent peripheral arterial disease and inflammatory burden
por: Cauley, Jane A., et al.
Publicado: (2016)

Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease
por: Kim, Gwang Sil, et al.
Publicado: (2022)

The effect of revascularization on recovery of mitochondrial respiration in peripheral artery disease: a case control study
por: Gratl, Alexandra, et al.
Publicado: (2021)

Comparison of the oxidative profiles before and after revascularization in peripheral arterial disease: a pilot study
por: Takeuchi, Kozo, et al.
Publicado: (2023)

Comparative Effectiveness Review of Antiplatelet Agents in Peripheral Artery Disease
por: Schmit, Kristine, et al.
Publicado: (2014)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

THE IMPACT OF THE COVID19 PANDEMIC ON PATIENTS WITH PERIPHERAL ARTERY DISEASE
por: Tanaka, John, et al.
Publicado: (2023)

Clinical outcomes of left main coronary artery disease patients undergoing three different revascularization approaches
por: Su, Chieh-Shou, et al.
Publicado: (2018)

Minimally invasive extracorporeal circulation in end-stage coronary artery disease patients undergoing myocardial revascularization
por: Condello, Ignazio, et al.
Publicado: (2021)

Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial
por: Galani, Jemi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1c7i9bcr7mlj91pdr16anelphp